Evolution of immunity to SARS-CoV-2

Adam K. Wheatley[1,2]*, Jennifer A. Juno[1]*, Jing J. Wang[3]*, Kevin J. Selva[1], Arnold Reynaldi[4], Hyon-Xhi Tan[1], Wen Shi Lee[1], Kathleen M. Wragg[1], Hannah G. Kelly[1,2], Robyn Esterbauer[1,2], Samantha K. Davis[1], Helen E. Kent[1,5], Francesca L. Mordant[1], Timothy E. Schlub[4,6], David L. Gordon[7], David S. Khoury[4], Kanta Subbarao[1,8], Deborah Cromer[4], Tom P. Gordon[3,9], Amy W. Chung[1], Miles P. Davenport[4], Stephen J. Kent[1,2,5]✉.

 *AKW, JAJ and JJW contributed equally

[1] Department of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia

[2] Australian Research Council Centre for Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Melbourne, Victoria, Australia

[3] Department of Immunology and Flinders Proteomics Facility, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia

[4] Kirby Institute, University of New South Wales, Kensington, New South Wales, Australia

[5] Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia

[6] Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia

[7] Department of Microbiology and Infectious Diseases, Flinders University and SA Pathology, Flinders Medical Centre, Adelaide, South Australia, Australia

[8] WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia

[9] Department of Immunology, SA Pathology, Flinders Medical Centre, Adelaide, South Australia, Australia

✉   Corresponding author. Address to Professor Stephen Kent, Department of Microbiology and Immunology, Doherty Institute, 792 Elizabeth St, Melbourne, Victoria, Australia 3000. Phone +61 3 8344 9939. Email: skent@unimelb.edu.au

The durability of infection-induced SARS-CoV-2 immunity has major implications

for public health mitigation and vaccine development. Animal studies[1,2] and the

scarcity of confirmed re-infection[3] suggests immune protection is likely, although the

durability of this protection is debated. Lasting immunity following acute viral

infection requires maintenance of both serum antibody and antigen-specific memory

B and T lymphocytes and is notoriously pathogen specific, ranging from life-long for

smallpox or measles[4], to highly transient for common cold coronaviruses (CCC)[5].

Neutralising antibody responses are a likely correlate of protective immunity and

exclusively recognise the viral spike (S) protein, predominantly targeting the receptor

binding domain (RBD) within the S1 sub-domain[6]. Multiple reports describe waning

of S-specific antibodies in the first 2-3 months following infection[7-12]. However,

extrapolation of early linear trends in decay might be overly pessimistic, with several

groups reporting that serum neutralisation is stable over time in a proportion of

convalescent subjects[8,12-17]. While SARS-CoV-2 specific B and T cell responses are

readily induced by infection[6,13,18-24], the longitudinal dynamics of these key memory

populations remains poorly resolved. Here we comprehensively profiled antibody, B

and T cell dynamics over time in a cohort recovered from mild-moderate COVID-19.

We find that binding and neutralising antibody responses, together with individual

serum clonotypes, decay over the first 4 months post-infection, as expected, with a

similar decline in S-specific CD4+ and circulating T follicular helper (cTFH)

frequencies. In contrast, S-specific IgG+ memory B cells (MBC) consistently

accumulate over time, eventually comprising a significant fraction of circulating

MBC. Modelling of the concomitant immune kinetics predicts maintenance of

serological neutralising activity above a titre of 1:40 in 50% of convalescent subjects

to 74 days, with probable additive protection from B and T cells. Overall, our study

suggests SARS-CoV-2 immunity after infection is likely to be transiently protective at

a population level. SARS-CoV-2 vaccines may require greater immunogenicity and

durability than natural infection to drive long-term protection.

We recruited a longitudinal cohort of 64 subjects who recovered from COVID-19

(Extended Data Fig 1). A total of 158 samples were collected between day 26 and 149

post-symptom onset, with samples nominally denoted as early ($\leq$50days),

intermediate (50-100 days) and late ($\geq$100 days) convalescence (Fig 1A). In early

convalescence, neutralisation activity was widespread with a median serological titre

of 52, which declined to 34 in late convalescence (Fig 1B). A mixed-effects

modelling approach found that a two-phase decay model best fit with the observed

decay of neutralisation titres across the cohort ($p < 0.00001$, likelihood ratio test), with

rapid decay evident over the first half of our time-series (half-life ($t_{1/2}$) prior to day 70

= 55 days), compared with slower decay in the second half ($t_{1/2}$ from day 70 = 519

days)(Fig 1B). The capacity of immune plasma to inhibit interaction of the SARS-

CoV-2 receptor binding domain (RBD) with soluble hACE2 receptor[19] waned with a

similar two-phase decay, dropping more rapidly before day 70 ($t_{1/2}$ = 238 days) and

slowing after day 70 ($t_{1/2}$ = 1912 days; Fig1C).

Plasma antibodies specific for SARS-CoV-2 S antigens (trimeric spike protein (S),

S1, S2 and RBD subdomains) and nucleocapsid (N) antigens were quantified

longitudinally using a multiplex bead array[25]. In contrast to neutralisation titres, decay

of S-specific IgG was best fit by a model of constant decay over the period of

observation ($t_{1/2}$ = 229 days), with rates of decay divergent for antibodies binding S1

($t_{1/2}$ =115 days), S2 ($t_{1/2}$ = 344 days) and RBD antigens ($t_{1/2}$ = 126; Fig 1D, Extended

Data Fig. 2). Kinetics of decay were broadly consistent between IgG1 and IgG2

subclasses, with IgG3 displaying a more rapid, two phase decline (Extended Data Fig.

2). Consistent with a previous report[26], we find N-specific IgG decays significantly

more rapidly than S-specific IgG ($t_{1/2}$ = 71 and 229 days respectively, p < 0.00001,

Fig 1D). In contrast to IgG, S-specific IgM and IgA1 fit a two-phase decay, with a

more rapid early decay ($t_{1/2}$ = 55 and 42 days respectively) followed by a slower

decay in late convalescence ($t_{1/2}$ = 118 and >1000 days respectively; Fig 1D). A

comparison of decay rates between neutralising activity and antibody binding

demonstrated that early neutralisation decay occurs at a similar rate to the early

decline in S, RBD and S1-specific IgM (Fig 1E, Extended Data Fig 2). Neutralisation

titre at both early and late convalescence was well correlated with serum inhibition of

RBD-ACE2 binding and S, S1 and RBD specific IgG, IgM (and to a lesser extent

IgA1) responses, as well as with S2 and N specific IgG responses (Extended Data Fig

3). Neutralising activity during early convalescence was the best correlate of long-

term maintenance of neutralisation responses (Spearman rho=0.88, p<0.00001;

Extended Data Fig 3). Serum inhibition of RBD-ACE2 binding and S1-specific IgG

responses in early infection were also well correlated with neutralisation titre in late

convalescence (Spearman rho=0.79, 0.81, respectively; Extended Data Fig 3).

However, in a multiple regression model, once early neutralisation activity was

included no other significant predictors were identified (p>0.15 for all other

variables).

The decay of polyclonal antibody in plasma may obscure a more complex picture of

the dynamics of individual antibody specificities. To resolve longitudinal serological

decay at the level of a single clonotype, we adapted a novel mass spectrometry (MS)-

based quantitative proteomics workflow developed for serum autoantibody

profiling[27,28] to track unique CDR-H3 peptides matching recovered S-specific

immunoglobulins sequences from convalescent subjects[19] (n=4; Extended Data Fig

4A, B). Consistent with the decay of polyclonal S-specific antibody in the blood, we

find a decline in the relative abundance over time for each unique clonotype

(Extended Data Fig. 4C), although absolute rates of decay did vary, suggesting the

kinetics might to some degree be clonotype-, epitope- or subject-specific.

Anti-viral memory B and T cell responses will likely make additive contributions to

long-term immunological protection against COVID-19. SARS-CoV-2-specific B cell

responses were measured longitudinally in 31 subjects where sufficient cells were

available (Fig 1A) using flow cytometry and fluorescent S and RBD probes as

previously described[19]. Following infection, frequencies of IgG+ S-specific memory

B cells increased over time irrespective of disease severity (Fig. 2A and 2B; gating in

Supplementary Fig. S1). In contrast, S-specific IgA+ MBC frequencies remained

relatively stable while IgM+ MBC frequencies decreased (Fig. 2B). IgG+ S-specific

MBC remain significantly elevated at the final relative to the first available sampling

(p<0.0001), contrasting with stable IgA+ (p=0.367) and declining IgM+ populations

(p<0.0001) (Fig. 2C). Assessment of the activation status of S-specific IgG+ MBC

using CD21/CD27 staining[29] demonstrated decreased proportions of "activated" MBC

and a return to a resting (CD27+CD21+) phenotype over time (Extended Data Fig 5).

Although present at comparatively low frequencies, the dynamics of RBD-specific

MBC largely mirrored that of the parental S-specific population (Extended Data Fig

6). Modelling the growth rates reveals IgG+ S-specific MBC frequencies had a

doubling time of 48 days in early convalescence, after which point the doubling time

slowed to 843 days, with IgG+ RBD-specific cells MBC broadly comparable

(doubling time = 58 days early, $t_{1/2}$ = 247 days late) (Extended Data Fig 7). The

consistent and sustained increase in S-specific IgG+ MBC frequencies over time

aligns with a prior report of SARS-CoV-2 convalescent subjects[13], and with reports

from other viral infections[30] or replicating viral vaccines [31,326]. Given the relatively

low level of somatic mutation observed in S-specific antibodies recovered from

convalescent subjects to date[6,19] comparative studies at 6-9 months post-infection will

be informative to understand the maturation of the humoral response over time and

the protective potential of stably retained MBC populations.

Anti-viral memory T cell responses have been associated with amelioration of disease

for respiratory infection such as influenza[33]. S-specific cTFH and conventional CD4+

and CD8+ memory T cells (Tmem), were quantified using activation induced marker

(AIM) assays [19,22] (Methods) following stimulation with overlapping S (split into S1

or S2) peptide pools (Fig. 3A, 3B). Frequencies of S-specific memory T cells were

dynamic over time and varied between individuals, with evidence of either rapid

decline or stable maintenance (Fig. 3C). Pairwise comparison of cTFH or CD4+

Tmem frequencies at the final visit relative to the first available sampling

demonstrated a significant reduction in S-specific responses over time (p=0.0031 for

cTFH, p=0.0224 for CD4+ Tmem; Fig. 3D). In contrast, frequencies of S-specific

CD8+ Tmem were stable at a population level (p=0.3247), although individual

responses were varied (Fig. 3D). Modelling of the decay rates estimated $t_{1/2}$ of 128

days for cTFH (95% CI 67, 1247) and 119 days for CD4+ Tmem (95% CI 66, 612;

Extended Data Fig 8). In contrast, the estimated decay of CD8+ responses is not

significantly different from 0 ($t_{1/2}$ = 670 days, 95% CI 97, -136; Extended Data Fig 8).

Therefore, while we and others[34,35] find that CD4+ responses are generally higher

during early convalescence, CD8+ T cell responses appear relatively stable during late

convalescence.

Multiple studies have reported CCC cross-reactive CD4+ T cells in SARS-CoV-2

uninfected subjects, largely recognising epitopes in S2[22,35,36]. To understand the

influence that recall of pre-existing CCC cross-reactive immunity might have on

decay, we contrasted S1 and S2 responses among the CD4+ T cell subsets. For cTFH,

a significant drop in S1 responses was observed over time (p=0.0028), while S2

responses were comparably stable but did similarly trend downward (p=0.0657)

(Extended Data Fig 9A,B). Analogous patterns were observed for the CD4+ Tmem

cells (Extended Data Fig 9C,D). Consequently, S2-specific cTFH and CD4+ Tmem

populations predominated over S1-directed responses (p=0.0147 and p=0.0021

respectively) in late convalescence (Extended Data Fig 9B,D).

Polyclonal T cell responses to S comprise an array of immunodominant and

subdominant epitopes; we therefore additionally tracked single CD4+ T cell epitopes

in a subset of 9 donors (Extended Data Fig 10A). Strikingly, we observed substantial

inter- and intra-individual variability in longitudinal epitope-specific responses

(Extended Data Fig 10B,C); in some subjects, all epitope-specific responses tracked

similarly while in others distinct epitope-specific responses would vary independently

over time. In most, but not all, cases, peptide responses tracked similarly between the

cTFH and Tmem populations (Extended Data Fig 10C). Overall, some degree of T

cell immunity remains readily detectable in most subjects 4 months after infection,

although longitudinal epitope-specific frequencies were markedly less predictable.

Deconvoluting the protective potential of the suite of concomitant immune responses

elicited by SARS-CoV-2 infection is challenging. The general decline of serological

immunity over time (Fig 4A) was similarly observed for most memory immune cell

subsets except for IgG+ and IgA+ MBC populations (Fig 4B). Importantly, rates of

immune decay are likely to stabilise over time to levels of homeostatic maintenance[37],

although this set point is not yet clear for SARS-CoV-2. Neutralising antibody is the

most widely accepted protective correlate against a range of human respiratory

viruses[38]. However, any relationship between *in vitro* neutralisation titres and *in vivo*

protection for SARS-CoV-2 is unclear at present. We therefore developed a

simulation model (see Methods) employing the estimated initial distributions of

neutralisation titres and decay rates across subjects, to predict the time for titres to

drop below a nominated cut-off of 1:40, selected based on the 1:40 hemagglutination

inhibition titre (a surrogate for neutralisation activity) widely used as the 50%

protective titre for influenza[39]. Notably, 43% of our cohort were already below this

threshold in early convalescence, with 64% of subjects dropping below this threshold

in late convalescence. Simulating a population of 1000 individuals, and running the

model 1000 times, we find the median time for 50% of the population to drop below a

titre of 1:40 was 74 days (Fig 4C; 95% confidence interval 46 to >1000 days).

Assuming early neutralisation titres predicted titres into late convalescence, our

simulation also allows us to estimate how higher initial levels of neutralisation may

affect the proportion of individuals maintaining titres above 1:40. We found that if

aiming for a median of 50% of individuals with a titre above 1:40 at one year, initial

neutralisation titres at about day 30 would need to be in the order of 2.1-fold higher

than that observed in our convalescent cohort (95% CI = no increase to 16.9-fold

increase required). It is important to emphasise that at present the in vitro

neutralisation titre required and the additive contribution of other immune responses

to protective immunity are unknown. In addition, our analysis assumes that immunity

to vaccination decays at a similar rate to infection, and that the decay of neutralisation

titre from day 70 to around 140 predicts immune decay over the first year. Despite the

limitations inherent in these assumptions, this analysis provides an approach to

estimating the target level of immune response necessary for effective vaccination.

Overall, we find that both neutralising and binding antibody responses decay as

expected after recovery from COVID-19, assessed using polyclonal assays and at the

level of single clonotypes. While incredibly durable protective antibody responses

have been reported for other viral infections such as measles and smallpox[4], our data

suggests that SARS-CoV-2 is more likely to mirror immunity to endemic CCC, where

serum antibody responses decline with a likelihood of increasing susceptibility to

homologous virus within 1-2 years[5]. Neutralising antibody is a presumed but not yet

proven correlate of immune protection for SARS-CoV-2. Assuming similar immune

kinetics, our modelling suggests SARS-CoV-2 vaccines would likely need to elicit

substantially more potent neutralising titres than infection to induce durable

protection. Encouragingly, many early vaccine candidates have exceeded this metric

when compared against sera from convalescent subjects in clinical trials reported to

date[40,41]. Persistence of serum antibody is unlikely to be the sole determinant of long-

lasting immunity, with anamnestic recall of stably maintained memory T and B cell

populations likely reducing infection or disease. The magnitude, quality and

protective potential of cellular responses against SARS-CoV-2 requires further

definition. Although T cell memory in the blood contracts several months post

infection, a rise in S-specific IgG+ memory B cells to a median level of ~0.8% of all

IgG+ memory B cells by 4 months suggests even mild-moderate COVID-19 induces

substantial cellular immune memory.

Materials and Methods

Ethics Statement

The study protocols were approved by the University of Melbourne Human Research

Ethics Committee (#2056689) and the Southern Adelaide Clinical Human Research

Ethics Committee (#39.034), and all associated procedures were carried out in

accordance with the approved guidelines. All participants provided written informed

consent in accordance with the Declaration of Helsinki.

Subject recruitment and sample collection

Subjects who had recovered from COVID-19 were recruited through contacts with the

investigators and invited to provide serial blood samples. Subject characteristics of

SARS-CoV-2 convalescent subjects are collated in Extended Data Fig 1. For all

participants, whole blood was collected with sodium heparin anticoagulant. Plasma

was collected and stored at -80ºC, and PBMCs were isolated via Ficoll-Paque

separation, cryopreserved in 10% DMSO/FCS and stored in liquid nitrogen.

Microneutralisation Assay

SARS-CoV-2 isolate CoV/Australia/VIC01/2020 [42] was passaged in Vero cells and

stored at -80C. Plasma was heat-inactivated at 56°C for 30 min. Plasma was serially-

diluted 1:20 to 1:10240 before addition of 100 $TCID_{50}$ of SARS-CoV-2 in

MEM/0.5% BSA and incubation at room temperature for 1 hour. Residual virus

infectivity in the plasma/virus mixtures was assessed in quadruplicate wells of Vero

cells incubated in serum-free media containing 1 µg/ml TPCK trypsin at 37°C/5%

CO2; viral cytopathic effect was read on day 5. The neutralising antibody titre is

calculated using the Reed/Muench method as previously described[43,44]. All samples

were assessed in two independent microneutralisation assays.

Expression of SARS-CoV-2 proteins

271
A set of proteins was generated for serological and flow cytometric assays. The

ectodomain of SARS-CoV-2 (isolate WHU1;residues 1 – 1208) was synthesised with

furin cleavage site removed and P986/987 stabilisation mutations[45], a C-terminal T4

trimerisation domain, Avitag and His-tag, expressed in Expi293 cells and purified by

Ni-NTA affinity and size-exclusion chromatography using a Superose 6 16/70 column

(GE Healthcare). SARS-CoV S was biotinylated using Bir-A (Avidity). The SARS-

CoV-2 RBD[46] with a C-terminal His-tag (residues 319-541; kindly provided by

Florian Krammer) was similarly expressed and purified.

SARS-CoV-2 bead-based multiplex assay

The isotypes and subclasses of SARS-CoV-2 specific antibodies were detected as

previously described[25]. Briefly, a panel of SARS-CoV-2 antigens including trimeric

S, S1 (Sino Biological), S2 (ACROBiosystems), NP (ACROBiosystems,) and RBD[46]

were coupled to magnetic COOH- bioplex beads (Biorad) using a two-step

carbodiimide coupling reaction. 20µl of bead mixture containing 1000 beads per

region and 20µl of 1:200 diluted plasma were added per well. SARS-CoV-2- specific

antibodies were detected using phycoerythrin (PE)-conjugated mouse anti-human

pan-IgG, IgG1, IgG2, IgG3, IgA1 or IgA2 (Southern Biotech) at 1.3µg/ml, 25µl per

well. For the detection of IgM, biotinylated mouse anti-human IgM (mAb MT22;

MabTech) was added at 1.3µg/ml, 25µl per well followed by streptavidin-PE (SA-PE;

Thermo Fisher) at 1μg/ml. Plates were acquired by a FLEXMAP 3D (Luminex).

Median fluorescence intensity (MFI) for each isotype/subclass detector was assessed.

Background subtraction was conducted, removing background of blank (buffer only)

wells. Multiplex assays were repeated twice as two independent experiments.

RBD-ACE2 binding inhibition multiplex bead-based assay

RBD protein was coupled to bioplex beads (Biorad) as described above. 20μl of RBD

multiplex bead suspension containing 500 beads per well, 20μl of biotinylated

Avitag-ACE2 (kindly provided by Dale Godfrey and Nicholas Gherardin), final

concentration of 12.5μg/ml per well, along with 1:100 dilution of each subject's

plasma were added to 384 well plates. Plates were covered and incubated at room

temperature (RT) whilst shaking for 2 hours, and then washed twice with PBS

containing 0.05% Tween20 (PBST). Biotinylated Avitag-ACE2 was detected using

40μl per well of SA-PE at 4μg/ml, incubated with shaking for 1 hour at RT. 10μl of

PE-Biotin amplifier (Thermo Fisher) at 10μg/ml was added and incubated for 1 hour

with shaking at RT. Plates were washed and acquired on a FLEXMAP 3D (Luminex).

Anti-SARS-CoV-2 RBD neutralising human IgG1 antibody (ACROBiosystems,

USA) was included as a positive control, in addition to COVID-19 negative plasma

and buffer only negative controls. The MFI of bound ACE2 was measured after

background subtraction of no ACE2 controls. Maximal ACE2 binding MFI was

determined by buffer only controls. % ACE2 binding inhibition was calculated as

100% - (% ACE2 binding MFI per sample/ Maximal ACE2 binding). RBD-ACE2

binding inhibition multiplex assays were repeated independently twice.

Flow cytometric detection of S- and RBD-specific memory B cells

Probes for delineating SARS-CoV-2 S-specific B cells within cryopreserved human PBMC were generated by sequential addition of streptavidin-PE (Thermofisher) to trimeric S protein biotinylated using recombinant Bir-A (Avidity). SARS-CoV-2 RBD protein was directly labelled to APC using an APC Conjugation Lightning-link kit (Abcam). Cells were stained with Aqua viability dye (Thermofisher). Monoclonal antibodies for surface staining included: CD19-ECD (J3-119) (Beckman Coulter), CD20 Alexa700 (2H7), IgM-BUV395 (G20-127), CD21-BUV737 (B-ly4), IgD-Cy7PE (IA6-2), IgG-BV786 (G18-145) (BD), CD14-BV510 (M5E2), CD3-BV510 (OKT3), CD8a-BV510 (RPA-T8), CD16-BV510 (3G8), CD10-BV510 (HI10a), CD27-BV605 (O323) (Biolegend), IgA-Vio450 (clone) (Miltenyi). Cells were washed, fixed with 1% formaldehyde (Polysciences) and acquired on a BD LSR Fortessa or BD Aria II.

Flow cytometric detection of antigen-specific cTFH, memory CD4+ T cells and memory CD8 T cells

Cryopreserved human PBMC were thawed and rested for four hours at 37°C. Cells were cultured in 96-well plates at 1×10^6 cells/well and stimulated for 20 hours with 2μg/peptide/mL of peptide pools (15mer, overlapping by 11) covering the S1 or S2 domains of SARS-CoV-2. Selected donors were also stimulated with SEB (1μg/mL) as a positive control, or individual peptides at 2ug/mL: NCTFEYVSQPFLMDL (S1 epitope; previously described in [47]); LPIGINITRFQTLLA (S1 epitope); GWTFGAGAALQIPFA (S2 epitope); ALQIPFAMQMAYRFN (S2 epitope); LLQYGSFCTQLNRAL (S2 epitope; [19,47]); QALNTLVKQLSSNFG (S2 epitope). Following stimulation, cells were washed, stained with Live/dead Blue viability dye (ThermoFisher), and a cocktail of monoclonal antibodies: CD27 BUV737 (L128),

CD45RA PeCy7 (HI100), CD20 BUV805 (2H7), (BD Biosciences), CD3 BV510

(SK7), CD4 BV605 (RPA-T4), CD8 BV650 (RPA-T8), CD25 APC (BC96), OX-40

PerCP-Cy5.5 (ACT35), CD69 FITC (FN50), CD137 BV421 (4B4-1) (Biolegend),

and CXCR5 PE (MU5UBEE, ThermoFisher). Cells were washed, fixed with 1%

formaldehyde and acquired on a BD LSR Fortessa using BD FACS Diva.

Mass spectrometry (MS)-based quantitative proteomics of serum anti-S1

antibodies. The workflow for anti-S1 proteomic profiling is shown in Extended Data

Figure 4A. Briefly, antibodies against SARS-CoV-2 S1 spike protein were affinity-

purified from convalescent plasma of COVID-19 subjects at different time points

using S1 protein-coupled magnetic beads (Acrobiosystems). IgG heavy chains were

isolated after reduced SDS-PAGE and digested with trypsin and chymotrypsin to

generate peptides for LC-MS/MS using a Thermo Scientific Orbitrap Exploris 480

mass spectrometer coupled to an Ultimate 3000 UHPLC (Dionex). De novo

sequencing data analysis was performed by Peaks studio X-plus software

(Bioinformatics Solution). Peptide sequences were referenced against recovered

heavy chain immunoglobulin sequences generated from single sorted S-specific

memory B cells[19] to identify matched CDR-H3 peptides. Anti-S1 clonotypic antibody

expression levels were monitored by parallel reaction monitoring (PRM) as described

previously[28,48]. Fragment ion extracted ion chromatograms (XICs) per CDR-H3

peptide were visualized in Skyline version 20.1.0.155 (University of Washington) and

inspected manually to ensure correct assignments. The annotated spectra of

individual peptides and their corresponding XICs are shown in Supplementary

Information.

Estimating the decay rates

We sought to predict the response variable (y_{ij} for patient i at timepoint j) as a

function of days post symptom onset, assay replicate (as a binary categorical variable)

and a random effect for each individual (both in in intercept and slope). The

dependency of the response variables on days post symptom onset can be modelled by

using one or two decay slopes. The model can be written as below:

$y_{ij} = \beta_0 + b_{0i} + \beta_1 R_{ij} + \beta_2 t_{ij} + b_{2i} t_{ij}$ – for a model with a single slope; and

$y_{ij} = \beta_0 + b_{0i} + \beta_1 R_{ij} + \beta_2 t_{ij} + b_{2i} t_{ij} + \beta_3 s_{ij} + b_{3i} s_{ij}$ – for a model with two

different slopes, in which:

$s_{ij} = \begin{cases} 0, & t_{ij} < T_0 \\ t_{ij} - T_0, & t_{ij} \geq T_{0.} \end{cases}$

The parameter β_0 is a constant (intercept), and b_{0i} is a patient-specific adjustment to

the overall intercept. The slope parameter β_2 is a fixed effect to capture the decay

slope before T_0; which also has a subject-specific random effect b_{2i}. To fit a model

with two different decay rates, an extra parameter β_3 (with a subject-specific random

effect b_{3i}) was added to represent the difference between the two slopes. Assay

variability between replicates was modelled as a single fixed effect β_1, in which we

coded the replicate as a binary categorical variable R_{ij}.

The response variables obtained were highly variable, containing zeros where the

value was below the limit of detection and contrasted with samples where very high

levels were observed. Thus, we performed log transformations of the non-zero data to

help normalize variability and censored every value less than 40 for the

microneutralisation data; every value less than 0.01 for the T cell and B cell data; and

every negative value for the multiplex data. More specifically, a mixed-effect

regression method that allows for censoring at the limit of detection was used to

estimate the parameters in the model. This was done by using *lmec* library in *R*, using

the ML algorithm to fit for the fixed effects[49]. We also tested if the decay of

serological response variables was fitted better by a single or two different decay

slopes (likelihood ratio test – based on the likelihood value and the difference in the

number of parameters). 95% CI for the fixed effect parameters was calculated based

on the standard error estimates, which can be obtained directly by using the *varFix*

function from *lmec* library. These analyses were carried out in *R* version 4.0.2.

Simulating the decay of serological neutralisation activity

To understand the decay in serum neutralisation we employed a simulation approach

using the parameters estimated from our mixed-effect censoring regression model of

decay. The fixed effect estimates averaged the intercept across experimental replicates

($\beta_0 + \beta_{1/2}$ from equations above) and random effects were randomly selected from a

multivariate normal distribution with covariance matrix taken from the mixed-effect

regression with censoring lmec object. The residual error standard deviation for

simulated data every 10 days was taken from the lmec object. The confidence interval

for the percentage of subjects with a neutralisation titre above 1:40 was estimated

empirically with the percentile method by repeating the simulation 1000 times, where

for each replicate the fixed effects were drawn from a normal distribution based on

their standard error (as well as randomly selected random effects). To estimate the

fold increase in initial neutralisation titre required to achieve >50% of individuals

with a titre above 40 at 1 year we assumed that the rate of decay was constant from

day 70 onwards and projected forward the expected titres in the simulated

populations. The median and confidence intervals for the proportion of individuals

with titre > 40 were calculated from these 1000 simulated populations.

Statistical Analyses

Associations between neutralisation, inhibition of ACE2 binding and antibody binding were assessed using both Spearman correlation, and multiple regression (R version 4.0.2). The geometric mean of replicate neutralisation measurements and the arithmetic mean of replicate measurements in other assays were used in the correlation and regression analyses for other measurements. Neutralisation titres below the limit of detection (a titre of 20) were assigned the arbitrary value 10 prior to calculating the geometric mean for the purposes of the Spearman correlation, where rank and not magnitude of the measurements is important. For the multiple regression analysis values below the limit of detection were set at the detection threshold and censoring regression was performed using the function *censReg (*from the *censReg* library[50]) to determine which measurements during early convalescence were significant predictors of neutralisation titre during late convalescence. Comparison of B and T cell frequencies at first and final sampling was performed using Wilcoxon Rank Sum test in GraphPad Prism 8. All statistical tests used were two sided.

Competing interests

The authors declare no competing interests.

Data Availability

All data are available from the corresponding author upon reasonable request.

Code Availability

All data analysis code can be made available on request.

Authors' contributions

A.K.W, J.A.J., J.J.W, H.-X.T., T.E.S., D.L.G., D.S.K., D.C., T.P.G, A.W.C., M.P.D., and S.J.K. designed the study and experiments. A.K.W., J.A.J., J.J.W., K.J.S, A.R., H.-X.T., W.S.L., K.M.W., H.G.K., R.E., S.K.D, H.E.K, F.L.M., T.E.S., and K.S. performed experiments. A.K.W., J.A.J., J.J.W, H.-X.T., W.S.L., A.R., D.S.K., T.E.S.,

D.C., K.S., M.P.D., S.J.K. analysed the experimental data. A.K.W, J.A.J., J.J.W,

K.J.S, T.E.S., D.S.K., D.C., M.P.D., and S.J.K. wrote the manuscript. All authors

reviewed the manuscript.

Acknowledgements
We thank the generous participation of the trial subjects for providing samples. We

thank E. Haycroft, E. Lopez, C. Nelson and T. Amarasena and C. Batten (University

of Melbourne) for excellent technical assistance. The SARS-CoV-2 RBD expression

plasmids were kindly provided by F. Krammer (Icahn School of Medicine at Mt

Sinai). Recombinant human ACE2 was kindly provided by N. Gherardin and D.

Godfrey (University of Melbourne). We acknowledge the Melbourne Cytometry

Platform (Melbourne Brain Centre node) for provision of flow cytometry services.

We thank T. Chataway and A. Colella (Flinders Proteomics Facility) for technical

support with quantitative proteomics. This study was supported by the Victorian

Government, an Australian government Medical Research Future Fund award

GNT2002073 (SJK, MPD, and AKW), the ARC Centre of Excellence in Convergent

Bio-Nano Science and Technology (SJK), an NHMRC program grant APP1149990

(SJK and MPD), NHMRC project grant GNT1162760 (AKW), an NHMRC-EU

collaborative award APP1115828 (SJK and MPD), the European Union Horizon 2020

Research and Innovation Programme under grant agreement 681137 (SJK), Emergent

Ventures Fast Grants (AWC), the Jack Ma Foundation (KS) and the A2 Milk

Company (KS). JAJ, DSK, and SJK are supported by NHMRC fellowships. JJW is

supported by Flinders University DVCR Fellowship and Flinders Health & Medical

Research Institute COVID-19 Research Grant. AKW, KS, DC and MPD are

supported by NHMRC Investigator grants. The Melbourne WHO Collaborating

Centre for Reference and Research on Influenza is supported by the Australian

Government Department of Health.

Figure 1 – Dynamics of serological responses to SARS-CoV-2

(**A**) Timeline of sample collection for each cohort participant (n=64 participants, 158

total samples). Samples included only in serological analysis are indicated in black

(n=33); samples included in both serological and cellular immune analysis are

indicated in red (n=31). Shaded areas indicate early (<50 days) and late (>100 days)

convalescent time periods, and dashed line indicates day 70 midpoint. (**B**)

Longitudinal microneutralisation endpoint titre and (**C**) inhibition of ACE2 binding

(%) for individuals. Best fit two-phase decay slope (red line) is indicated. (**D**)

Individual kinetics and best fit decay slopes for IgG binding to spike (S), IgG binding

to nucleoprotein (N), IgM binding to S and IgA1 binding to S. (**E**) Estimated half-life

and confidence intervals of the neutralising antibody titre before day70 (red) and after

day70 post-symptom onset (blue) are indicated as dashed vertical lines. Estimated

early decay rates and confidence intervals for serological inhibition of ACE2 and

antibody binding titres are indicated (single phase decay is shown in grey, two phase

decay indicated in red/blue).

Figure 2 - Quantification of S-specific memory B cell responses.

(**A**) Staining class-switched B cells (CD19+IgD-) with SARS-CoV-2 spike probes

allows the tracking of antigen-specific cells in subjects previously infected with

SARS-CoV-2. (**B**) Frequencies of S-specific IgG+, IgA+ or IgM+ memory B cells as

a proportion of CD19+CD20+IgD- B cells in PBMC samples were assessed

longitudinally (n=31 subjects). (**C**) Comparison of S-specific IgG+, IgA+ or IgM+

memory B cell frequencies at the earliest and latest timepoint available for each

individual (n=31). Statistics assessed by two-tailed Wilcoxon test.

Figure 3 - Quantification of antigen-specific CD4+ and CD8+ T cell responses.

(**A**) Representative staining of AIM markers (CD25, OX-40) on CD4+ Tmem cells

(CD3+CD4+CD8-CD45RA-CXCR5-) after stimulation with vehicle, S1 or S2 peptide

pools in longitudinal samples from 1 participant (top row, day 33; middle row, day

61; bottom row, day 143). (**B**) Representative staining of AIM markers (CD69,

CD137) on CD8+ Tmem cells (CD3+CD8+CD4-non-naïve) in longitudinal samples

from 1 participant (top row, day 41; middle row, day 85; bottom row, day 120). (**C**)

Longitudinal changes in the frequency of total S (S1+S2 pool responses after

background subtraction)-specific responses among cTFH, CD4+ and CD8+ Tmem

subsets (n=31). (**D**) Comparison of S-specific T cell responses at the earliest and latest

timepoint available for each individual (n=31). Statistics assessed by two-tailed

Wilcoxon test.

Figure 4 – Modelling of concomitant immune responses after COVID-19

(**A**) Rates of decay of serological neutralisation activity, ACE2 binding inhibition, and

S-specific IgG, IgM and IgA following recovery from SAR-CoV-2 infection. (**B**)

Fitted Growth and decay rates for S-specific memory T cell and B cell frequencies in

PBMC. (**C**) Simulation of elicitation and decay of serological neutralisation activity in

1000 individuals based on distributions observed in our SARS-CoV-2 convalescent

cohort. The simulation was repeated 1000 times to estimate the proportion of

individuals maintaining a neutralisation titre above 1:40 across multiple simulations

(median and 95% confidence intervals shown in red).

Extended data figure 1. Demographic and clinical characteristics of the

convalescent COVID-19 cohort.

Extended data figure 2: Fitting of the decline in antibody binding across different immunoglobulin isotypes.

The best-fit model and half-lives are shown for the fitting of the decay of antibody binding to different SARS-CoV-2 antigens (n=64 subjects). Two-phase decay is indicated by red (before day 70) and blue (after day 70) shaded areas. No shading indicates where single-phase decay provided the best fit.

Extended Data Figure 3: Correlation of antibody binding and ACE2 inhibition with neutralisation.

A heat-map of Spearman correlations between neutralisation titre and the serological measurements of antibody binding (by isotype and antigen). Correlations were assessed in early ($\leq$50 days, left column n=54 subjects) and late ($\geq$100 days, right middle column, n=47 subjects) convalescence in all subjects were data was available. The association between early antibody binding and late neutralisation is also shown (right column, n=47 subjects). All correlations are Spearman correlations. *P$\leq$0.05, **P$\leq$0.01, ***P$\leq$0.001.

Extended Data Figure 4: MS-based quantification of immunoprecipitated S1-specific clonotypic antibodies.

(A) Combined B cell receptor sequencing and proteomics platform enables identification and quantification of circulating anti-S1 antibodies. S1-specific IgG was purified from plasma of SARS-CoV-2 convalescent subjects using antigen-coupled magnetic beads and heavy chains subject to LC-MC/MS. Peptide spectra are searched

against B-cell receptor sequencers recovered from single sorted S-specific memory B

cells from the same individuals to identify clonotypes based upon CDR-H3 amino

acid sequence. Clonotype specific peptides are then used as barcodes for relative

quantitative parallel reaction monitoring (PRM) for tracking in longitudinal plasma

samples. Targeted peptides are monitored during elution from HPLC and individual

peptides quantified based on abundance chromatography curves. **(B)** Clonotypes

identified based on matched CDR-H3 sequences from S1-specific plasma IgG and B

cell receptor sequences from SARS-CoV-2 convalescent subjects (n=4). **(C)**

Longitudinal changes in the relative plasma abundance of anti-S1 clonotypes within

four convalescent subjects over time. The quantity of each reference peptide is

expressed as area under the curve (AUC) derived from extracted ion chromatography.

Extended Data Figure 5: Activation status of S-specific IgG+ memory B cells.

(A) Memory B cell phenotypes identified by CD21 and CD27 co-staining of S+

CD19+CD20+IgD-IgG+ B cells (red) overlaid onto parental CD19+CD20+IgD-IgG+

B cells (black) and **(B)** the corresponding frequencies of "activated" (CD27+CD21-)

or resting (CD27+CD21+) in in PBMC samples were assessed longitudinally (n=31

subjects).

Extended Data Figure 6: RBD-specific memory B cell dynamics.

(A) Frequencies of RBD-specific IgG+, IgA+ or IgM+ memory B cells as a

proportion of CD19+CD20+IgD- B cells in PBMC samples were assessed

longitudinally. **(B)** Comparison of RBD-specific IgG+, IgA+ or IgM+ memory B cell

frequencies at the earliest and latest timepoint available for each individual (n=31).

Statistics assessed by two-tailed Wilcoxon test.

Extended Data Figure 7: Fitting of the kinetics of S- and RBD-specific memory B cell responses over time.

The best-fit half-lives are shown for the fitting of the growth and/or decay of S- or RBD-specific memory B cells (n=31 subjects). Two-phase decay is indicated by red (before day 70) and blue (after day 70) shaded areas. No shading indicates where a single-phase decay model was used to fit the data.

Extended Data Figure 8: Fitting of the decline in SARS-CoV-2-specific T cells over time.

The best-fit half-lives are shown for the fitting of the decay of cTFH, CD4+ Tmem and CD8+ Tmem specific to total S (S1+S2 responses combined), S1 or S2 peptide pools (n=31 subjects). In all cases decay was fit with a single-phase decay model with the half-lives shown.

Extended Data Figure 9: S1 and S2-specific CD4+ T cell responses.

(A, C) Representative staining of AIM markers following S1 and S2 peptide pool stimulation among **(A)** cTFH (CD3+CD4+CD8-CD45RA-CXCR5+) or **(C)** CD4+ Tmem cells and longitudinal cohort analysis (n=31). **(B, D)** Comparison of S1 or S2-specific **(B)** cTFH or **(D)** CD4+ Tmem responses at the earliest and latest visit for each participant, as well as paired frequency of S1 versus S2 responses at the initial or final visit (n=31). Statistics assessed by two-tailed Wilcoxon test.

Extended Data Figure 10: Epitope-specific CD4+ T cell responses.

593   **(A)** Representative staining of AIM markers following S1 or S2 peptide pool or

594   individual peptide stimulation among the CD4+ Tmem population. **(B,C)**

595   Longitudinal peptide-specific frequencies in individual subjects (n=9; solid line,

596   CD4+ Tmem; dashed line, cTFH) for whom **(B)** multiple or **(C)** single epitopes were

597   identified.

References

1. Deng, W., *et al.* Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. *Science (New York, N.Y.)* **369**, 818-823 (2020).
2. Chandrashekar, A., *et al.* SARS-CoV-2 infection protects against rechallenge in rhesus macaques. *Science (New York, N.Y.)* **369**, 812-817 (2020).
3. To, K.K., *et al.* COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* (2020).
4. Amanna, I.J., Carlson, N.E. & Slifka, M.K. Duration of humoral immunity to common viral and vaccine antigens. *The New England journal of medicine* **357**, 1903-1915 (2007).
5. Edridge, A.W., *et al.* Coronavirus protective immunity is short-lasting. *medRxiv*, 2020.2005.2011.20086439 (2020).
6. Robbiani, D.F., *et al.* Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature* (2020).
7. Ibarrondo, F.J., *et al.* Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. *The New England journal of medicine* (2020).
8. Crawford, K.H., *et al.* Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. *medRxiv*, 2020.2008.2006.20169367 (2020).
9. Isho, B., *et al.* Mucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients. *medRxiv*, 2020.2008.2001.20166553 (2020).
10. Yao, X.-Y., *et al.* Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases. *medRxiv*, 2020.2007.2018.20156810 (2020).
11. Wu, J., *et al.* SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. *medRxiv*, 2020.2007.2021.20159178 (2020).
12. Beaudoin-Bussières, G., *et al.* Decline of humoral responses against SARS-CoV-2 Spike in convalescent individuals. *bioRxiv*, 2020.2007.2009.194639 (2020).
13. Rodda, L.B., *et al.* Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. *medRxiv*, 2020.2008.2011.20171843 (2020).
14. Seow, J., *et al.* Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. *medRxiv*, 2020.2007.2009.20148429 (2020).
15. Muecksch, F., *et al.* Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. *medRxiv*, 2020.2008.2005.20169128 (2020).
16. Wajnberg, A., *et al.* SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. *medRxiv*, 2020.2007.2014.20151126 (2020).
17. Brochot, E., *et al.* Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. *medRxiv*, 2020.2005.2012.20098236 (2020).
18. Seydoux, E., *et al.* Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. *Immunity* **53**, 98-105.e105 (2020).
19. Juno, J.A., *et al.* Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. *Nature medicine* (2020).

20. Schulien, I*., et al.* Ex vivo detection of SARS-CoV-2-specific
CD8+ T cells: rapid induction, prolonged contraction, and formation of
functional memory. *bioRxiv*, 2020.2008.2013.249433 (2020).

21. Neidleman, J*., et al.* SARS-CoV-2-specific T cells exhibit phenotypic features
of robust helper function, lack of terminal differentiation, and high
proliferative potential. *Cell Rep Med*, 100081 (2020).

22. Grifoni, A*., et al.* Targets of T Cell Responses to SARS-CoV-2 Coronavirus in
Humans with COVID-19 Disease and Unexposed Individuals. *Cell* **181**, 1489-
1501.e1415 (2020).

23. Braun, J*., et al.* SARS-CoV-2-reactive T cells in healthy donors and patients
with COVID-19. *Nature* (2020).

24. Habel, J.R*., et al.* Suboptimal SARS-CoV-2-specific CD8+ T-cell response
associated with the prominent HLA-A*02:01 phenotype. *medRxiv*,
2020.2008.2017.20176370 (2020).

25. Selva, K.J*., et al.* Distinct systems serology features in children, elderly and
COVID patients. *medRxiv*, 2020.2005.2011.20098459 (2020).

26. Grandjean, L*., et al.* Humoral Response Dynamics Following Infection with
SARS-CoV-2. *medRxiv*, 2020.2007.2016.20155663 (2020).

27. Singh, M*., et al.* Lymphoma Driver Mutations in the Pathogenic Evolution of
an Iconic Human Autoantibody. *Cell* **180**, 878-894.e819 (2020).

28. Wang, J.J*., et al.* Molecular Profiling and Clonal Tracking of Secreted
Rheumatoid Factors in Primary Sjögren's Syndrome. *Arthritis & rheumatology*
(Hoboken, N.J.) **70**, 1617-1625 (2018).

29. Lau, D*., et al.* Low CD21 expression defines a population of recent germinal
center graduates primed for plasma cell differentiation. *Science immunology*
2(2017).

30. Davis, C.W*., et al.* Longitudinal Analysis of the Human B Cell Response to
Ebola Virus Infection. *Cell* **177**, 1566-1582.e1517 (2019).

31. Matsuda, K*., et al.* Prolonged evolution of the memory B cell response
induced by a replicating adenovirus-influenza H5 vaccine. *Science*
immunology **4**(2019).

32. Wec, A.Z*., et al.* Longitudinal dynamics of the human B cell response to the
yellow fever 17D vaccine. *Proceedings of the National Academy of Sciences*
of the United States of America **117**, 6675-6685 (2020).

33. Brown, D.M., Dilzer, A.M., Meents, D.L. & Swain, S.L. CD4 T cell-mediated
protection from lethal influenza: perforin and antibody-mediated mechanisms
give a one-two punch. *Journal of immunology (Baltimore, Md. : 1950)* **177**,
2888-2898 (2006).

34. Grifoni, A*., et al.* Targets of T Cell Responses to SARS-CoV-2 Coronavirus in
Humans with COVID-19 Disease and Unexposed Individuals. *Cell* (2020).

35. Weiskopf, D*., et al.* Phenotype and kinetics of SARS-CoV-2-specific T cells
in COVID-19 patients with acute respiratory distress syndrome. *Science*
immunology **5**(2020).

36. Mateus, J*., et al.* Selective and cross-reactive SARS-CoV-2 T cell epitopes in
unexposed humans. *Science (New York, N.Y.)* (2020).

37. Crotty, S*., et al.* Cutting edge: long-term B cell memory in humans after
smallpox vaccination. *Journal of immunology (Baltimore, Md. : 1950)* **171**,
4969-4973 (2003).

38. Plotkin, S.A. Updates on immunologic correlates of vaccine-induced
protection. *Vaccine* **38**, 2250-2257 (2020).

39. Cox, R.J. Correlates of protection to influenza virus, where do we go from
here? *Human vaccines & immunotherapeutics* **9**, 405-408 (2013).
40. Keech, C.*, et al.* Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike
Protein Nanoparticle Vaccine. *The New England journal of medicine* (2020).
41. Jackson, L.A.*, et al.* An mRNA Vaccine against SARS-CoV-2 - Preliminary
Report. *The New England journal of medicine* (2020).
42. Caly, L.*, et al.* Isolation and rapid sharing of the 2019 novel coronavirus
(SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia.
Med J Aust **212**, 459-462 (2020).
43. Houser, K.V.*, et al.* Prophylaxis With a Middle East Respiratory Syndrome
Coronavirus (MERS-CoV)-Specific Human Monoclonal Antibody Protects
Rabbits From MERS-CoV Infection. *The Journal of infectious diseases* **213**,
1557-1561 (2016).
44. Subbarao, K.*, et al.* Prior infection and passive transfer of neutralizing
antibody prevent replication of severe acute respiratory syndrome coronavirus
in the respiratory tract of mice. *Journal of virology* **78**, 3572-3577 (2004).
713
Methods References:
45. Wrapp, D.*, et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion
conformation. *Science (New York, N.Y.)* **367**, 1260-1263 (2020).
46. Amanat, F.*, et al.* A serological assay to detect SARS-CoV-2 seroconversion
in humans. *Nature medicine* (2020).
47. Peng, Y.*, et al.* Broad and strong memory CD4+ and CD8+ T cells induced by
SARS-CoV-2 in UK convalescent individuals following COVID-19. *Nature
immunology* (2020).
48. Wang, J.J., Colella, A.D., Beroukas, D., Chataway, T.K. & Gordon, T.P.
Precipitating anti-dsDNA peptide repertoires in lupus. *Clinical and
experimental immunology* **194**, 273-282 (2018).
49. Vaida, F. & Liu, L. Fast Implementation for Normal Mixed Effects Models
With Censored Response. *J Comput Graph Stat* **18**, 797-817 (2009).
50. Henningsen, A. censReg: Censored Regression (Tobit) Models. (2017).
728

Figure 1 – Dynamics of serological responses to SARS-CoV-2

(**A**) Timeline of sample collection for each cohort participant (n=64 participants, 158 total samples). Samples included only in serological analysis are indicated in black (n=33); samples included in both serological and cellular immune analysis are indicated in red (n=31). Shaded areas indicate early (≤50 days) and late (≥100 days) convalescent time periods, and dashed line indicates day 70 midpoint. (**B**) Longitudinal microneutralisation endpoint titre and (**C**) inhibition of RBD-ACE2 binding (%) for individuals. Best fit two-phase decay slope (red line) is indicated. (**D**) Individual kinetics and best fit decay slopes for IgG binding to spike (S), IgG binding to nucleoprotein (N), IgM binding to S and IgA1 binding to S. (**E**) Estimated half-life and confidence intervals of the neutralising antibody titre before day70 (red) and after day70 post-symptom onset (blue) are indicated as dashed vertical lines. Estimated early decay rates and confidence intervals for serological inhibition of ACE2 and antibody binding titres are indicated (single phase decay is shown in grey, two phase decay indicated in red/blue).

Figure 2 - Quantification of S-specific memory B cell responses.

(**A**) Staining class-switched B cells (CD19+IgD-) with SARS-CoV-2 spike probes allows the tracking of antigen-specific cells in subjects previously infected with SARS-CoV-2. (**B**) Frequencies of S-specific IgG+, IgA+ or IgM+ memory B cells as a proportion of CD19+CD20+IgD- B cells in PBMC samples were assessed longitudinally (n=31 subjects). (**C**) Comparison of S-specific IgG+, IgA+ or IgM+ memory B cell frequencies at the earliest and latest timepoint available for each individual (n=31). Statistics assessed by two-tailed Wilcoxon test.

Figure 3 - Quantification of antigen-specific CD4+ and CD8+ T cell responses.

(**A**) Representative staining of AIM markers (CD25, OX-40) on CD4+ Tmem cells (CD3+CD4+CD8-CD45RA-CXCR5-) after stimulation with vehicle, S1 or S2 peptide pools in longitudinal samples from 1 participant (top row, day 33; middle row, day 61; bottom row, day 143). (**B**) Representative staining of AIM markers (CD69, CD137) on CD8+ Tmem cells (CD3+CD8+CD4-non-naïve) in longitudinal samples from 1 participant (top row, day 41; middle row, day 85; bottom row, day 120). (**C**) Longitudinal changes in the frequency of total S (S1+S2 pool responses after background subtraction)-specific responses among cTFH, CD4+ and CD8+ Tmem subsets (n=31). (**D**) Comparison of S-specific T cell responses at the earliest and latest timepoint available for each individual (n=31). Statistics assessed by two-tailed Wilcoxon test.

Figure 4 – Modelling of concomitant immune responses after COVID-19

(**A**) Rates of decay of serological neutralisation activity, ACE2 binding inhibition, and S-specific IgG, IgM and IgA following recovery from SAR-CoV-2 infection. (**B**) Fitted Growth and decay rates for S-specific memory T cell and B cell frequencies in PBMC. (**C**) Simulation of elicitation and decay of serological neutralisation activity in 1000 individuals based on distributions observed in our SARS-CoV-2 convalescent cohort. The simulation was repeated 1000 times to estimate the proportion of individuals maintaining a neutralisation titre above 1:40 across multiple simulations (median and 95% confidence intervals shown in red).

Extended Data Figures

	Full Cohort (n=64)	Cellular Analysis Cohort (n=31)
Age, median (IQR)	55 (62, 49)	52 (56, 31)
Gender, % female (n)	43.8% (28)	45.2% (14)
Disease severity, % (n) - mild	68.8% (44)	74.2% (23)
- moderate	23.4% (15)	16.1% (5)
- severe	7.8% (5)	9.7% (3)
Positive PCR test, % (n)	84.4% (54)	83.9% (26)

Extended data figure 1. Demographic and clinical characteristics of the convalescent COVID-19 cohort.

Extended data figure 2: Fitting of the decline in antibody binding across different immunoglobulin isotypes.

The best-fit model and half-lives are shown for the fitting of the decay of antibody binding to different SARS-CoV-2 antigens (n=64 subjects). Two-phase decay is indicated by red (before day 70) and blue (after day 70) shaded areas. No shading indicates where single-phase decay provided the best fit.

Correlation with neutralisation

	Early	Late	Early level vs. late neutralisation
Neutralisation	1.00***	1.00***	0.88***
ACE2 binding inhibition	0.73***	0.81***	0.79***
Anti–S IgG	0.47***	0.55***	0.52***
Anti–S1 IgG	0.71***	0.84***	0.81***
Anti–S2 IgG	0.58***	0.60***	0.59***
Anti–RBD IgG	0.70***	0.78***	0.76***
Anti–N IgG	0.47***	0.71***	0.47**
Anti–S IgG1	0.39**	0.42**	0.47**
Anti–S1 IgG1	0.69***	0.83***	0.78***
Anti–S2 IgG1	0.51***	0.53***	0.52***
Anti–RBD IgG1	0.64***	0.76***	0.71***
Anti–N IgG1	0.41**	0.68***	0.43**
Anti–S IgG2	−0.06	0.14	−0.11
Anti–S1 IgG2	0.23	0.40**	0.29
Anti–S2 IgG2	0.08	0.17	0.16
Anti–RBD IgG2	0.25	0.47***	0.39*
Anti–N IgG2	0.07	0.57***	0.27
Anti–S IgG3	0.46***	0.52***	0.55***
Anti–S1 IgG3	0.59***	0.68***	0.65***
Anti–S2 IgG3	0.44***	0.41**	0.47**
Anti–RBD IgG3	0.60***	0.55***	0.57***
Anti–N IgG3	0.43**	0.61***	0.50**
Anti–S IgG4	0.17	0.38*	0.20
Anti–S1 IgG4	0.20	0.29	0.04
Anti–S2 IgG4	0.18	0.20	0.03
Anti–RBD IgG4	0.01	0.03	−0.14
Anti–N IgG4	0.08	0.63***	0.10
Anti–S IgM	0.45***	0.51***	0.52***
Anti–S1 IgM	0.61***	0.68***	0.69***
Anti–S2 IgM	0.18	0.05	0.28
Anti–RBD IgM	0.56***	0.47***	0.64***
Anti–N IgM	−0.04	−0.14	−0.03
Anti–S IgA1	0.29*	0.18	0.09
Anti–S1 IgA1	0.36**	0.44**	0.25
Anti–S2 IgA1	0.35**	0.27	0.25
Anti–RBD IgA1	0.30*	0.39**	0.22
Anti–N IgA1	0.31*	0.07	0.31
Anti–S IgA2	0.32*	0.32*	0.14
Anti–S1 IgA2	0.40**	0.57***	0.33*
Anti–S2 IgA2	0.45***	0.44**	0.37*
Anti–RBD IgA2	0.40**	0.51***	0.29
Anti–N IgA2	0.39**	0.30*	0.37*

ρ scale: 1.0, 0.5, 0.0, −0.5, −1.0

Extended Data Figure 3: Correlation of antibody binding and ACE2 inhibition with neutralisation.

A heat-map of Spearman correlations between neutralisation titre and the serological measurements of antibody binding (by isotype and antigen). Correlations were assessed in early (≤50 days, left column n=54 subjects) and late (≥100 days, right middle column, n=47 subjects) convalescence in all subjects were data was available. The association between early antibody binding and late neutralisation is also shown (right column, n=47 subjects). All correlations are Spearman correlations. *P≤0.05, **P≤0.01, ***P≤0.001.

A

B

Subject	IGHV	IGHD	IGHJ	Translated CDR-H3 sequences	Matched CDR-H3 peptide sequences
CP04	1-3	3-10	6	ARILGTTRKYFDDSERDGMDVW	KYFDDSERDGMDVWGQGTTVTVSSASTK (pep1)
					KYFDDSER (pep2)
	4-34	3-22	4	ARDRYHYYDSSGYSKNYRHFDYW	DRYHYYDSSGYSK (pep3)
CP08	1-69	3-10	6	VRGMYASGNYRGSDFFYGMDVW	GMYASGNYR (pep4)
				VRGLYASGNFRGSDFFYGMDVW	GLYASGNFR (pep5)
				VRGLYASGSYRGSDFFYGMDVW	GLYASGSYR (pep6)
	1-69	6-13	6	ARVGAPIERTSSSWHYYYYGMDVW	VGAPIER (pep7)
	4-31	6-6	4	ARGFYEVYSSPTIKEYYFDYW	GFYEVYSSPTIK (pep8)
	3-7	3-16	4	ARVKINPYYDYVWGSYRYSRILDYW	YDYVWGSYR (pep9)
CP63	1-69	3-22	4	ARLGRGDYDSSGYYKVYFDYW	GDYDSSGYYK (pep10)
FCP01	1-46	3-10	6	SRGITLVQGVVRALRPGSKEYYYYGLDVW	YCSRGITL (pep11)
					GITLVQGVVR (pep12)
					GFTLVQGVVR (pep13)
					VQGVVRAL (pep14)
					ALRPGSKEYY (pep15)
					TLVQGVVR (pep16)

C

Extended Data Figure 4: MS-based quantification of immunoprecipitated S1-specific clonotypic antibodies.

(**A**) Combined B cell receptor sequencing and proteomics platform enables identification and quantification of circulating anti-S1 antibodies. S1-specific IgG was purified from plasma of SARS-CoV-2 convalescent subjects using antigen-coupled magnetic beads and heavy chains subject to LC-MC/MS. Peptide spectra are searched against B-cell receptor sequencers recovered from single sorted S-specific memory B cells from matched individuals to identify clonotypes based upon CDR-H3 amino acid sequence. Clonotype specific peptides are then used as barcodes for relative quantitative parallel reaction monitoring (PRM) for tracking in longitudinal plasma samples. Targeted peptides are monitored during elution from HPLC and individual peptides quantified based on abundance chromatography curves. (**B**) Clonotypes identified based on matched CDR-H3 sequences from S1-specific plasma IgG and B cell receptor sequences from SARS-CoV-2 convalescent subjects (n=4). (**C**) Longitudinal changes in the relative plasma abundance of anti-S1 clonotypes within four convalescent subjects over time. The quantity of each reference peptide is expressed as area under the curve (AUC) derived from extracted ion chromatography.

Extended Data Figure 5: Activation status of S-specific IgG+ memory B cells.

(**A**) Memory B cell phenotypes identified by CD21 and CD27 co-staining of S+CD19+CD20+IgD-IgG+ B cells (red) overlaid onto parental CD19+CD20+IgD-IgG+ B cells (black) and (**B**) the corresponding frequencies of "activated" (CD27+CD21-) or resting (CD27+CD21+) in in PBMC samples were assessed longitudinally (n=31 subjects).

Extended Data Figure 6: RBD-specific memory B cell dynamics.

(**A**) Frequencies of RBD-specific IgG+, IgA+ or IgM+ memory B cells as a proportion of CD19+CD20+IgD- B cells in PBMC samples were assessed longitudinally. (**B**) Comparison of RBD-specific IgG+, IgA+ or IgM+ memory B cell frequencies at the earliest and latest timepoint available for each individual (n=31). Statistics assessed by two-tailed Wilcoxon test.

Extended Data Figure 7: Fitting of the kinetics of S- and RBD-specific memory B cell responses over time.

The best-fit half-lives are shown for the fitting of the growth and/or decay of S- or RBD-specific memory B cells (n=31 subjects). Two-phase decay is indicated by red (before day 70) and blue (after day 70) shaded areas. No shading indicates where a single-phase decay model was used to fit the data.

Extended Data Figure 8: Fitting of the decline in SARS-CoV-2-specific T cells over time.

The best-fit half-lives are shown for the fitting of the decay of cTFH, CD4+ Tmem and CD8+ Tmem specific to total S (S1+S2 responses combined), S1 or S2 peptide pools (n=31 subjects). In all cases decay was fit with a single-phase decay model with the half-lives shown.

Extended Data Figure 9: S1 and S2-specific CD4+ T cell responses.

(**A, C**) Representative staining of AIM markers following S1 and S2 peptide pool stimulation among (**A**) cTFH (CD3+CD4+CD8-CD45RA-CXCR5+) or (**C**) CD4+ Tmem cells and longitudinal cohort analysis (n=31). (**B, D**) Comparison of S1 or S2-specific (**B**) cTFH or (**D**) CD4+ Tmem responses at the earliest and latest visit for each participant, as well as paired frequency of S1 versus S2 responses at the initial or final visit (n=31). Statistics assessed by two-tailed Wilcoxon test.

A

B

Longitudinal epitope-specific CD4+ T cell responses

C

Extended Data Figure 10: Epitope-specific CD4+ T cell responses.

(**A**) Representative staining of AIM markers following S1 or S2 peptide pool or individual peptide stimulation among the CD4+ Tmem population. (**B,C**) Longitudinal peptide-specific frequencies in individual subjects (n=9; solid line, CD4+ Tmem; dashed line, cTFH) for whom (**B**) multiple or (**C**) single epitopes were identified.

Supplementary Fig. S1: Gating strategy for resolving antigen-specific B cells and surface isotypes.

After doublet exclusion (FSC-A vs FSC-H) and lymphocyte gating (FSC-A vs SSC-A), live CD19+IgD-CD20+ B cells were gated based on surface immunoglobulin expression (IgM, IgG, IgA). Binding to SARS-CoV-2 spike (S) and/or SARS-CoV-2 RBD probes was assessed for each population. Memory B cell phenotypes were identified by CD21 and CD27 co-staining.

Supplementary Fig. S2: Gating strategy for quantifying antigen-specific T cells.
Lymphocytes were identified by FSC/SSC, followed by doublet exclusion (FSC-A vs FSC-H), and exclusion of dead or CD20+ cells. After gating on CD3, single positive CD4 or CD8 T cell subsets were identified. CD8 Tmem were gated as non-naïve (CD27+CD45RA+) cells, and assessed for co-expression of CD69 and CD137 following stimulation. CD4 T cells were gated as cTFH (CXCR5+CD45RA-) or Tmem (CXCR5-CD45RA-), and assessed for co-expression of OX-40 and CD25 following stimulation.

Supplementary Fig. S3: Representative annotated MS/MS spectra (left panel) and their corresponding extracted ion chromatograms (XICs; right panel). The peptides used in PRM analyses are the matched clonotypic CDR-H3 peptides (pep1-16). Underlined amino acid indicates a post translational modification: <u>M</u> (oxidised methionine), <u>W</u> (oxidised tryptophan), <u>K</u> (carbamidomethylated lysine), <u>D</u> (carbamidomethylated aspartate), <u>C</u> (carbamidomethylated cysteine), and <u>Y</u> (acetylated tyrosine). The sequences, m/z and z of each individual peptides are shown on the top of their annotated MS/MS spectra. Matched b ions are indicated in blue and y ions are in red. m=mass, z=charge.